The National Medical Products Administration has approved the market launch of injectable Fezalonumab.

Recently, the National Medical Products Administration approved the listing of the injectable Fizezomib monoclonal antibody declared by Tianjing Biotechnology Co., Ltd. This product, used in combination with lenalidomide and dexamethasone, is for adult patients with multiple myeloma who have previously received at least one line of treatment. The launch of this product provides new treatment options for relevant patients.